TIGIT and neoplasm: These findings elucidate a mechanism through which TIGIT checkpoint inhibitors modify immunosuppressive tumor microenvironments and underscore the importance of FcγR engagement in developing anti-TIGIT antibodies (Guan et al., 2024b).